Impacts of sarcopenia on prostate cancer patients undergoing docetaxel chemotherapy

被引：0
|
作者：
Lin, Jacky [1 ]
Tyler, Gemma [1 ]
Linker, Joshua [1 ]
Shen, Dennis [1 ]
Zwan, Benjamin [2 ]
Ho, Nathan [1 ]
Chan, Matthew [3 ,4 ]
Arasaratnam, Malmaruha [3 ,4 ]
机构：
[1] Univ New England, Armidale, NSW, Australia
[2] Gosford Hosp, Dept Radiat Oncol, Gosford, NSW, Australia
[3] Gosford Hosp, Dept Med Oncol, Gosford, NSW, Australia
[4] Wyong Hosp, Gosford, NSW, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：27 / 27
页数：1
相关论文
共 50 条
  • [21] DOCETAXEL: RECHALLENGE AT PSA RELAPSE AFTER DOCETAXEL CHEMOTHERAPY AT HORMONE REFRACTORY PROSTATE CANCER
    Firek, P.
    Pfister, D.
    Thueer, D.
    Brehmer, B.
    Epplen, R.
    Heidenreich, A.
    EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (02) : 283 - 283
  • [22] Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer
    Heinemann, Lucy
    Simpson, Guy R.
    Boxall, Angela
    Kottke, Timothy
    Relph, Kate L.
    Vile, Richard
    Melcher, Alan
    Prestwich, Robin
    Harrington, Kevin J.
    Morgan, Richard
    Pandha, Hardev S.
    BMC CANCER, 2011, 11
  • [23] Multinucleated polyploidy drives resistance to Docetaxel chemotherapy in prostate cancer
    Karuna Mittal
    Shashi Donthamsetty
    Ramneet Kaur
    Chunhua Yang
    Meenakshi V Gupta
    Michelle D Reid
    Da Hoon Choi
    Padmashree C G Rida
    Ritu Aneja
    British Journal of Cancer, 2017, 116 : 1186 - 1194
  • [24] Significance of docetaxel in the chemotherapy of hormone-refractory prostate cancer
    Wolff, JM
    ONKOLOGIE, 2003, 26 : 37 - 40
  • [25] Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer
    Lucy Heinemann
    Guy R Simpson
    Angela Boxall
    Timothy Kottke
    Kate L Relph
    Richard Vile
    Alan Melcher
    Robin Prestwich
    Kevin J Harrington
    Richard Morgan
    Hardev S Pandha
    BMC Cancer, 11
  • [26] Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer
    Pandha, S.
    Heinemann, L.
    Simpson, G. R.
    Boxall, A.
    Relph, K.
    Morgan, R.
    BRITISH JOURNAL OF SURGERY, 2011, 98 : 47 - 48
  • [27] Multinucleated polyploidy drives resistance to Docetaxel chemotherapy in prostate cancer
    Mittal, Karuna
    Donthamsetty, Shashi
    Kaur, Ramneet
    Yang, Chunhua
    Gupta, Meenakshi V.
    Reid, Michelle D.
    Choi, Da Hoon
    Rida, Padmashree C. G.
    Aneja, Ritu
    BRITISH JOURNAL OF CANCER, 2017, 116 (09) : 1186 - 1194
  • [28] Plasma chromogranin A: Clinical implications in patients with castrate resistant prostate cancer receiving docetaxel chemotherapy
    Sarkar, Debansu
    Singh, S. K.
    Mandal, Arup K.
    Agarwal, Mayank M.
    Mete, Uttam K.
    Kumar, Santosh
    Mavuduru, Ravimohan S.
    Prasad, Rajendra
    CANCER BIOMARKERS, 2010, 8 (02) : 81 - 87
  • [29] Docetaxel Chemotherapy Retreatment in Patients with Metastatic Hormone Refractory Prostate Cancer: Efficacy and Toxicity Analysis
    Ansari, J.
    Zarkar, A.
    Hussain, S. A.
    Tanguay, J.
    Bliss, J.
    Glaholm, J.
    CLINICAL ONCOLOGY, 2009, 21 (01) : 67 - 67
  • [30] Effect of docetaxel chemotherapy on the activity of a gonadotropin releasing hormone vaccine in patients with advanced prostate cancer
    Triozzi, PL
    Bolger, GB
    Neidhart, J
    Rinehart, JJ
    Saleh, M
    Allen, KO
    Sellers, S
    Waddell, MJ
    PROSTATE, 2005, 65 (04): : 316 - 321
12345